Registration & Co�ee

Co�ee Break

Welcome Speech by Leonard Sachs, Managing Director, Sachs Associates

“Drug Chess: Planning a Few Moves Ahead of the Competition” by Peter Kolchinsky, Portfolio Manager & Managing Director, RA Capital Management, LLC

07:20

08:10

08:20

Industry Roundtable: Pharma-Biotech PipelineChaired by:Je�rey Bockman, EVP, Oncology Practice Head, De�ned Health, a Cello Health businessPanelists:Asthika Goonewardene, Senior Biotech Analyst, Bloomberg IntelligenceFrancis Kern, Executive Director, Oncology Search & Evaluation, Global Business Development, Daiichi Sankyo, Inc.Ji Li, EVP, Global Head of Business Development, BeiGene Ltd.John DeYoung, Vice President, Oncology Business Development, P�zer, Inc.Peter Thompson, Private Equity Partner, OrbiMed Advisors, LLC

09:00

09:40

“Selective AXL Inhibition as a Potential Cornerstone of Combination Cancer Therapy”by Richard Godfrey, CEO, BerGenBio ASA10:20

10:00

DealMaking and M&A PanelCo-Chaired by:Jonathan Kfoury, Managing Director, L.E.K. ConsultingMichael Margolis, Co-Head of Healthcare Investment Banking, Oppenheimer & Co., Inc.Panelists:Andrew Hass, Senior Advisor, Oncology External Innovation, Eli Lilly & Co.Chris Sheldon, Head of Oncology Search & Evaluation, AstraZenecaGuillaume Vignon, Senior Vice President Business Development, BeiGene Ltd.Matthias Müllenbeck, Director Global Oncology L&DB, Merck KGaA

10:40

11:20

Latest Developments in IO & Combination Therapies PanelCo-Chaired by:Mark Breidenbach, Executive Director & Senior Analyst, Biotechnology, Oppenheimer & Co., Inc.William Kuziel, Oncology Search & Evaluation, Global Business Development, Daiichi Sankyo, Inc.Panelists:Carlos de Sousa, CEO, Immunicum ABJohn Haurum, CEO, F-star Biotechnology Ltd.Lisa Decker, Vice President, Business Development, Nektar TherapeuticsLoic Vincent, Head Oncology & Immunology Research Partnerships, Takeda Pharmaceuticals InternationalTakashi Kei Kishimoto, CSO, Selecta Biosciences, Inc.

Cancer Vaccines & Neo Antigens: Evaluating Latest Progress PanelChaired by:Matthias Müllenbeck, Director Global Oncology L&BD, Merck KGaAPanelists:Frederic Ors, CEO, Immunovaccine, Inc.Igor Matushansky, CMO, Global Head Research & Development, Hookipa Biotech AGKarin Jooss, EVP of Research & CSO, Gritstone OncologyMarc Dechamps, Acting CEO, eTheRNA immunotherapies NVPamela Caroll, SVP, Immuno-Oncology, Genocea Biosciences, Inc.

12:20 12:20

12:0012:00

12:10

12:20

12:30

Selecta Biosciences, Inc.[NASDAQ: SELB]

TapImmune, Inc. [NASDAQ: TPIV]

Immunicum AB[STO: IMMU]

12:40 Networking Lunch

Lycera

ISA Pharmaceuticals B.V.

Madison Vaccines Incorporated

VLP Therapeutics

PR Companies Track A Moderated by

Raghuram Selvaraju, H.C. Wainwright & Co., LLC

PR Companies Track BModerated by:

Kumaraguru Raja, Brookline Capital Markets

PR Companies Track CModerated by:

Robin Davison, New Science Global Healthcare Fund

IMMUNO-ONCOLOGYUSAWaldorf Astoria Chicago Hotelst

BD&L AND INVESTMENT FORUM1 June 2018ANNUAL

4th

Connenct to Wi-Fi:

� WAChicago-Guest� :

13:40

Advances in Cell & Gene Therapies PanelCo-Chaired by:Axel Hoos, SVP, TA Head of Oncology R&D, GlaxoSmithKlineGregory Frost, Managing Director, F1BioVentures, LLCPanelists:Charles Wilson, President & CEO, Unum Therapeutics, Inc.Helen Tayton-Martin, CBO, Adaptimmune Ltd.Peter Hoang, President & CEO, TapImmune, Inc.Raghuram Selvaraju, Managing Director, Senior Healthcare Analyst, H.C. Wainwright & Co., LLCTimothy Herpin, CBO, Caribou Biosciences, Inc.

16:10

Early Stage Innovation PanelChaired by: Robert Silverman, Personalized Healthcare (PHC) Business Strategy & Partnering, Roche Innovation CenterPanelists:Gary Sclar, Vice President, Dana-Farber Innovations, Dana-Farber Cancer InstituteHilary Hehman, Director, Partnerships & Alliances, Fred Hutchinson Cancer Research CenterLee Greenberger, CSO, The Leukemia & Lymphoma Society (LLS)Nathan Gianneschi, Founder, Vybyl BiopharmaRobert Radinsky, VP, Oncology Scienti�c Innovation, Johnson & Johnson Innovation

16:50

Investor RoundtableCo-Chaired by:Bibhash Mukhopadhyay, Principal, NEABoris Peaker, Managing Director, Biotechnology Equity Research, Cowen, Inc.Panelists:Arjun Goyal, Co-Founder & Managing Director, Vida VenturesBrad Loncar, Private Investor, Portfolio Manager, Loncar Investments, LLCLuke Li, Partner & Managing Director, Ally Bridge GroupYogen Saunthararajah, Professor of Medicine, Sta� Physician & Co-Leader of the Developmental Therapeutics Program, Cleveland ClinicYuwen Liu, Founding Partner & CEO, Bohe Angel Fund

12:40 Networking Lunch

16:00 Co�ee Break

17:30 Networking Reception

18:30 End of the 4th IOBDLI Forum

14:40 14:40 14:40

15:00

15:20

15:40 15:40 15:40

15:20 15:20

15:00 15:00

OSE Immunotherapeutics[EPA: OSE]

Genocea Biosciences, Inc. [NASDAQ: GNCA]

Selvita S.A.[WSE: SLV]

Immunovaccine, Inc.[TSE: IMV] Hookipa Biotech AG

Hemispherx Biopharma, Inc.[NYSEAMERICAN: HEB]

eTheRNA immunotherapies NV

F-star Biotechnology Ltd.

Numab Therapeutics AG

Triumvira Immunologics, Inc.

Medicenna Therapeutics, Corp.[TSE: MDNA]

PR Companies Track DModerated by:

Juan Pedro Serrate, Edison Group

PR Companies Track EModerated by:

Leonards Sachs, Sachs Associates

PR Companies Track FModerated by:

Robin Davison, New Science Global Healthcare Fund

Supported by:Silver Sponsor:

ACM Biolabs Pte Ltd.